Results 141 to 150 of about 34,901 (267)

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations

, 2020
Rachel L. Soon, Justin R. Lenhard, Zackery P. Bulman, Patricia N. Holden, Pamela Kelchlin, Judith N. Steenbergen, Lawrence V. Friedrich, Alan Forrest, Brian T. Tsuji   +8 more
openalex   +1 more source

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent [PDF]

, 2019
Melissa D. Barnes, Vijay Kumar, Christopher R. Bethel, Samir H. Moussa, John P. O’Donnell, Joseph Rutter, Caryn E. Good, Kristine M. Hujer, Andrea M. Hujer, Steve H. Marshall, Barry N. Kreiswirth, Sandra S. Richter, Philip N. Rather, Michael R. Jacobs, Krisztina M. Papp‐Wallace, Focco van den Akker, Robert A. Bonomo   +16 more
openalex   +1 more source

Cryptic susceptibility to penicillin/β-lactamase inhibitor combinations in emerging multidrug-resistant, hospital-adapted Staphylococcus epidermidis lineages [PDF]

, 2023
Xiaoliang Ba, Claire Raisen, Olivier Restif, Lina Cavaco, Carina Vingsbo Lundberg, Jean Lee, Benjamin P. Howden, Mette Damkjær Bartels, Birgit Strommenger, Ewan M. Harrison, Anders Rhod Larsen, Mark A. Holmes, Jesper Larsen   +12 more
openalex   +1 more source

Programming Next‐Generation Synthetic Biosensors by Genetic Circuit Design

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Synthetic biology enables genetic circuit‐based biosensing to detect diverse targets, process signals, and transduce them into readable outputs or intracellular regulatory activities. However, field deployment and real‐world application of such synthetic biosensors face considerable challenges in sensitivity, specificity, speed, stability, and ...
Yuanli Gao, Cheng Huang, Jiaxuan Deng, Lei Wang, Baojun Wang   +4 more
wiley   +1 more source

Structure-guided drug repurposing identifies aristospan as a potential inhibitor of β-lactamase: insights from virtual screening and molecular dynamics simulations

Frontiers in Pharmacology
The rise of β-Lactamase mediated antibiotic resistance is a major concern for public health; hence, there is an urgent need to find new treatment approaches.
Moyad Shahwan, Moyad Shahwan, Mohd Shahnawaz Khan, Azna Zuberi, Nojood Altwaijry, Anas Shamsi   +5 more
doaj   +1 more source

Trapping and Characterization of a Reaction Intermediate in Carbapenem Hydrolysis by \u3cem\u3eB. cereus\u3c/em\u3e Metallo-β-lactamase [PDF]

, 2008
Metallo-β-lactamases hydrolyze most β-lactam antibiotics. The lack of a successful inhibitor for them is related to the previous failure to characterize a reaction intermediate with a clinically useful substrate.
Tioni, Mariana F., Llarrull, Leticia l., Poeylaut-Palena, Andrés A., Martí, Marcelo A., Saggu, Miguel, Periyannan, Gopal R., Mata, Ernesto G., Bennett, Brian, Murgida, Daniel H., Vila, Alejandro J.   +9 more
core   +1 more source

A Case Series of Hypermucoid Klebsiella pneumoniae Liver Abscess in Caucasian Americans Without Travel History: An Epidemiologic Shift?

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Hypervirulent Klebsiella pneumoniae (hvKp) is an emerging cause of community‐acquired pyogenic liver abscess (PLA), classically described in East and Southeast Asia. We report two cases of hvKp‐associated PLA in Caucasian women of American origin with no history of international travel, animal exposure, or Asian food consumption. Both patients
Krishna Sai Kiran Sakalabaktula, Sameer Kumar Majety, Sri Ratna Divya Nanduri, Divya Durga, David Kreps, Devi Prasad Botu, Gopichand Muppana   +6 more
wiley   +1 more source

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 608-617, March 2026.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka, Michael Lawton, Tom Chu, Gary S. Friedman, Katrina Peron, Stefan R. Sultana, Warren E. Glaab, Nicholas M. P. King   +7 more
wiley   +1 more source

Metallo-β-Lactamase Inhibitor Phosphonamidate Monoesters

ACS Omega, 2022
Katarzyna Palica, Manuela Vorácová, Susann Skagseth, Anna Andersson Rasmussen, Lisa Allander, Madlen Hubert, Linus Sandegren, Hanna-Kirstirep Schrøder Leiros, Hanna Andersson, Máté Erdélyi   +9 more
doaj   +1 more source

Drug Discovery in the Field of β-Lactams: An Academic Perspective

Antibiotics
β-Lactams are the most widely prescribed class of antibiotics that inhibit penicillin-binding proteins (PBPs), particularly transpeptidases that function in peptidoglycan synthesis.
Lian M. C. Jacobs, Patrick Consol, Yu Chen   +2 more
doaj   +1 more source